iOncologi Secures Key Patent for RNA-Based Cancer Immunotherapy as Studies Link COVID-19 mRNA Vaccines to Enhanced Checkpoint Inhibitor Response
核心洞察
iOncologi (搜索) has received a foundational U.S. patent for RNA-based formulations that enhance tumor responsiveness to immune checkpoint inhibitor therapy, exclusively licensed from the University of Florida Research Foundation.
New research published in Nature Biomedical Engineering demonstrates how non-tumor-antigen-specific mRNA formulations can amplify type-I interferon responses and trigger epitope spreading to reprogram the tumor microenvironment.
Clinical data presented at ESMO 2025 showed that SARS-CoV-2 mRNA vaccination correlated with significantly improved overall survival in checkpoint-treated melanoma and non-small cell lung cancer patients.
iOncologi (搜索), Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, announced that the United States Patent and Trademark Office has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor therapy. The patent, owned by the University of Florida Research Foundation and exclusively licensed to iOncologi, supports the company's UNIFYRs (搜索)™ (UNiversal Immune FortifYing RNAs) platform.
Breakthrough Research Validates RNA-Based Immune Reprogramming
The newly granted patent builds on discoveries published in Nature Biomedical Engineering, where researchers at the University of Florida revealed how non-tumor-antigen-specific mRNA formulations can amplify early type-I interferon responses and trigger epitope spreading. This mechanism reprograms the tumor microenvironment and restores sensitivity to immune checkpoint inhibitors.
"By demonstrating that non-antigen-encoding, systemically delivered mRNA-lipid formulations can re-educate both innate and adaptive immunity, we're establishing the biological basis that underlies iOncologi (搜索)'s UNIFYRs (搜索)™ platform," said Dr. Elias Sayour, Professor of Neurosurgery and Pediatrics at the University of Florida, co-inventor, and senior author of the study.
Dr. Duane Mitchell, co-inventor and co-founder of iOncologi (搜索), emphasized the universal potential of this approach: "By demonstrating that a single RNA backbone can restore responsiveness to immune checkpoint inhibitors across multiple tumor types, we are charting a course toward a universal strategy to overcome immune resistance in cancer and unlock responses in patients who currently do not benefit from immunotherapy."
Clinical Evidence from ESMO 2025
Supporting the mechanistic foundation, new translational data were presented by Dr. Adam Grippin of MD Anderson Cancer Center during the European Society for Medical Oncology Annual Congress in Berlin on October 19, 2025. The presentation, titled "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade," reported that mRNA-based immune activation achieved through SARS-CoV-2 mRNA vaccination correlated with significantly improved overall survival among checkpoint-treated melanoma and non-small cell lung cancer patients.
These clinical findings closely reflect the mechanistic principles first described in the Nature Biomedical Engineering study and have been independently reported in mainstream media for their potential to enhance immunotherapy response in cancer patients.
Implications for Cancer Treatment
"These findings represent a turning point for patients facing immunotherapy resistance," said Edgardo Rodriguez-Lebron, PhD, Chief Executive Officer of iOncologi (搜索). "The implications extend well beyond patient outcomes — RNA-based immune activation could revitalize immune checkpoint inhibitor franchises that have struggled to show benefit in solid tumors."
The UNIFYRs (搜索)™ platform leverages multilamellar RNA-lipid particles designed to fortify and broaden immune checkpoint inhibitor efficacy across multiple tumor types. This represents a new therapeutic modality positioned at the intersection of oncology, RNA technology, and systems immunology.
Strategic Development Path
With the newly granted patent, iOncologi (搜索) strengthens its intellectual property portfolio in RNA-based immune reprogramming. The company, headquartered in Gainesville, Florida, with a wholly owned subsidiary in Basel, Switzerland, aims to work with strategic partners to accelerate the path to patients facing immunotherapy resistance in solid tumors.